Introduction {#S5}
============

Uric acid is the end product of purine metabolism. The prevalence of hyperuricemia (uric acid ≥ 420μmol/L in males, ≥ 360μmol/L in females) has increased rapidly over the past two decades ([@R1], [@R2]). The connection between hyperuricemia and gout has long been known; however, hyperuricemia is much more common than gout. Increasing evidence shows that hyperuricemia is a risk factor for metabolic syndrome([@R3]) and cardiovascular diseases([@R4]).

Although obesity and hyperuricemia are correlated, the genetic background of this association is not well understood. Several candidate genes, including *SLC2A9* and *ABCG2* ([@R5], [@R6]), have been identified in genome-wide association studies (GWASs) and follow-up replications. To investigate the possible role of these genes in obese individuals, we performed a genome wide association study (GWAS) for plasma uric acid in 1,060 obesity cases/controls using our previous genotyping data for body weight traits([@R7]).

Methods and Procedures {#S6}
======================

Subjects {#S7}
--------

All subjects gave informed consent, and the protocol was approved by the Committee on Studies Involving Human Beings at the University of Pennsylvania. Five hundred twenty (520) European-American obesity cases (BMI\>35 kg/m^2^) and 540 normal-weight controls (BMI\<25 kg/m^2^) were selected for analysis from ongoing studies ([@R8]). Clinical characteristics have been described previously ([@R9]). In 961 samples with uric acid data, 924 were females.

Genotyping {#S8}
----------

DNA was extracted from whole blood or lymphoblastoid cell lines using a high-salt method. All samples were genotyped on Illumina HumanHap550 SNP arrays (Illumina, San Diego, CA) with \~550,000 SNP markers, at the Center for Applied Genomics, Children's Hospital of Philadelphia.

Data analyses {#S9}
-------------

Uric acid outliers (\> 3SD) were deleted from the data set. Quantitative association studies were performed using PLINK 1.07 that based on the Wald test([@R10]). To investigate the plausible influence of obesity status on uric acid levels, we also performed GWAS separately in obesity cases (BMI\>35kg/m^2^) and normal weight controls (BMI\<27kg/m^2^). Female-only analyses were also carried out after quantitative associations were conducted in all samples.

Results {#S10}
=======

Of the 1,060 obese cases and normal controls, 961 had plasma uric acid data. Thirty-seven (37) of those 961 individuals were male; 924 were female. Average age of the 961 subjects was 41.9±9.1 years (range, 16--65 years). Distributions of uric acid levels in all samples, cases, and controls are shown separately in [Table 1](#T1){ref-type="table"}. Q-Q plots showed normal distributions of uric acid levels in those 3 groups ([Figure 1](#F1){ref-type="fig"}).

Significant associations were found between *SLC2A9* gene SNPs and plasma uric acid. The most significant result was for the SNP rs6449213 (all samples, P=3.15×10^−12^; female-only samples, P=2.29×10^−12^)([Table 2](#T2){ref-type="table"}).

DIP2C gene SNP rs877282 also reached genome wide significance (P=4,56×10^−8^). Many SNPs in the DIP2C gene also showed associations (P\<1×10^−5^) ([Table 3](#T3){ref-type="table"}).

Weaker associations (P\<1×10^−5^) were found in *F5, PXDNL, FRAS1, LCORL, and MICAL2*gene SNPs. All 5 genes had multiple SNPs that associated with uric acid levels (3.05×10^−6^\< P \<1× 10^−4^)([Table 3](#T3){ref-type="table"}).Three coding region non-synonymous SNPs in the coagulation factor V (*F5*) gene, rs6030(Met 1764 Val), rs4525 (His 865 Arg), and rs4524 (Lys 858 Arg), were associated with plasma uric acid, P values of those 3 SNPs for BMI adjusted uric acid were 3.05 × 10^−6^, 0.00018, and 0.00017, respectively.

Besides *SLC2A9*, 3 previous found uric acid related genes *ABCG2*(rs2622605, P=0.0026), *SLC17A1*(rs3799344, P=0.0017), and *RREB1* (rs1615495, P =0.00055) received marginal support in our study ([Table 4](#T4){ref-type="table"}).

Discussion {#S11}
==========

Hyperuricemia has been considered as an independent risk factor of cardiovascular diseases and type 2 diabetes. Single gene mutations, including deficiency of hypoxanthine guanine phosphoribosyltransferase, lead to hyperuricemia; however, the risk attributable to these genes in the general population is minor([@R11]).

Large (\>10,000 individuals) GWASs and meta-analyses have shown that many genes are associated with plasma uric acid levels, including eight genes/regions (*SLC2A9*([@R5], [@R12], [@R13]), *ABCG2*([@R6]), *SLC22A11*, *SLC17A1*, *GCKR*, *R3HDM2-INHBC* gene region, *RREB1*, and *PDZK1*) that exceeded the genome-wide association level (P\<10^−7^)([@R14]). *SLC2A9* has the most significant association with uric acid so far, which could explain 3.5% of uric acid variation in the general population ([@R5]).

*SLC2A9 (GLUT-9)* is a major transporter of uric acid. It controls uric acid influx in the basolateral and apical surface of the kidney proximal convoluted tubule (PCT).*SLC2A9* is highly expressed in kidney and liver. Interestingly, *ABCG2* is an efflux uric acid transporter that is expressed in the apical surface of the PCT. The *SLC2A9* and *ABCG2* associations are among the strongest of all uric acid associations so far ([@R14]).

Uric acid and glucose transport are often coupled, but *SLC2A9* is not a major glucose/fructose transporter. In our study, uric acid levels correlated with fasting glucose. It is possible that *SLC2A9* polymorphisms account for the uric acid--glucose connection. However, the *SLC2A9* gene alone likely does not explain the 20% rate for hyperuricemia and almost the same rate for insulin resistance in general populations. Other genes with relatively minor genetic relative risk and/or gene--gene interactions may account for the rest of the genetic background for hyperuricemia.

The strength of the associations of *SLC2A9* gene SNPs and uric acid was well beyond the threshold for genome-wide significance. This is particularly notable given the moderate sample size (961 individuals). The *SLC2A9* associations have been replicated in several GWASs and follow-up association studies ([@R5], [@R6], [@R13], [@R14]), including European, African-American ([@R15]), and Japanese populations. Although this is not the first study to examine a European American population, we are interested in the *SLC2A9* association in extremely obese individuals. In our study, the BMI-adjusted uric acid yielded more significant association with *SLC2A9* polymorphisms than the unadjusted plasma uric acid. It is said that *SLC2A9* is not the major glucose transporter, although it is the main uric acid transporter in proximal convoluted tubule([@R16]). In our subjects, uric acid was correlated with almost all body weight, lipid (except LDL), and insulin resistance phenotypes (P\<0.001, data not shown). However, no direct association was found between *SLC2A9*gene-region SNPs and these other phenotypes([@R7]). These results suggest that the phenotypic associations between uric acid levels and metabolic syndrome phenotypes are through pathways independent of SLC2A9..

All uric acid associated genes found in our GWAS, including *SLC2A9, DIP2C* (Homo sapiens DIP2 disco-interacting protein 2 homolog C (Drosophila)), F5 (coagulation factor V), *FRAS1*( Fraser syndrome 1), *PXDNL* (Homo sapiens peroxidasin homolog (Drosophila)-like), *LCORL* (ligand dependent nuclear receptor corepressor-like), and *MICAL2* (microtubule associated monoxygenase, calponin and LIM domain containing 2), , are expressed in kidney and/or liver. It is hard to predict functional connections among those genes and plasma uric acid levels, although we have already known that some genes have functions in transcription regulations (*DIP2C*and *LCORL*) and mesenchymal/epithelial transition (*FRAS1*).

Venous thromboembolism, insulin resistance, and hyperuricemia are correlated in general populations. Many studies have shown that Factor V (*F5*) mutations are associated with factor V Leiden thrombophilia characterizedby deep vein thrombosis ([@R17]), however, no established connection between factor V and uric acid has been reported.

The SLC2A9 associations remained significant in both obese cases and controls. Several associations, including MICAL2, FRAS1, and LCORL, were more significant in obese individuals, while F5 was more significant in normal weight controls. ([Table 4](#T4){ref-type="table"}). Although some of these associations varied in obese cases and controls, however, none of these genes were among the top BMI associations that found in our GWAS ([@R7]).

We have failed to replicated associations on *SLC22A11, GCKR*, and *PDZK1* genes that reported by previous large sample sized GWASs([@R18], [@R19]).We could not explain if those lack of association were due to a smaller sample size, but no marginal significant association (P\<0.05) was found in either original or BMI adjusted uric acid levels.

In summary, two genes/chromosome regions reached genome wide association significance (P\< 1× 10^−7^, 550K SNPs) in our GWAS : *SLC2A9*, the chromosome 2 60.1 Mb region (rs6723995), and the *DIP2C* gene region. Five other genes (*F5*, *PXDNL, FRAS1, LCORL,* and *MICAL2*) yielded P\<1× 10^−5^. Four previous reported associations were replicated in our study, including *SLC2A9*, *ABCG2, RREB*, and the *SLC17A1*.
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###### 

Traits distributions of plasma uric acid in obese individuals (BMI\>35kg/m^2^), normal weight (BMI\<25kg/m^2^), and combined samples

                N     Minimum   Maximum   Mean    Std. Deviation   Skewness   Kurtosis
  ------------- ----- --------- --------- ------- ---------------- ---------- ----------
  **ALL**                                                                     
  Uric acid     962   1.500     8.800     4.667   1.4037           0.441      −0.219
  **FEMALE**                                                                  
  Uric acid     926   1.500     8.800     4.602   1.3628           0.441      −0.219
  **BMI\>35**                                                                 
  Uric acid     487   2.200     9.100     5.523   1.258            0.127      −0.095
  **BMI\<25**                                                                 
  Uric acid     472   1.500     6.300     3.768   0.881            0.147      −0.344

###### 

Significant associations between SLC2A9 gene SNPs and uric acid

  CHR   SNP          bp         *P* all subjects   *P* cases      *P* controls    gene
  ----- ------------ ---------- ------------------ -------------- --------------- ----------
  4     rs6449213    9603313    3.15 ×10^−12^      1.61 ×10^−7^   1.01 ×10^−12^   *SLC2A9*
  4     rs1014290    9610959    1.13 ×10^−9^       3.59 ×10^−6^   4.26 ×10^−12^   *SLC2A9*
  4     rs7660895    9594543    1.47 ×10^−9^       8.48 ×10^−7^   1.91 ×10^−9^    *SLC2A9*
  4     rs6832439    9533417    5.64 ×10^−11^      6.09 ×10^−6^   3.19 ×10^−12^   *SLC2A9*
  4     rs13129697   9536065    1.12 ×10^−10^      2.53 ×10^−6^   3.48 ×10^−10^   *SLC2A9*
  4     rs13131257   9590987    9.17 ×10^−11^      1.15 ×10^−5^   1.44 ×10^−11^   *SLC2A9*
  4     rs737267     9543842    2.73 ×10^−11^      7.34 ×10^−6^   1.79 ×10^−12^   *SLC2A9*
  4     rs10805364   9884616    1.67 ×10^−9^       0.00019        1.41 ×10^−12^   *SLC2A9*
  4     rs4698014    9895399    1.67 ×10^−9^       0.00069        7.55 ×10^−13^   *SLC2A9*
  4     rs4698036    9940392    2.89 ×10^−9^       0.0013         7.78 ×10^−12^   *SLC2A9*
  4     rs714436     9923765    2.48 ×10^−8^       0.00072        6.46 ×10^−11^   *SLC2A9*
  4     rs10022911   9749649    3.29 ×10^−6^       0.0057         5.42 ×10^−13^   *SLC2A9*
  4     rs17420080   9954646    3.53 ×10^−8^       0.00051        1.55 ×10^−10^   *SLC2A9*
  4     rs4698050    10019846   2.05 ×10^−8^       0.0022         1.22 ×10^−10^   *SLC2A9*
  4     rs4643800    10016670   1.08 ×10^−7^       0.0030         8.53 ×10^−11^   *SLC2A9*
  4     rs12498956   9559803    3.14 ×10^−7^       0.00026        8.71 ×10^−7^    *SLC2A9*
  4     rs4447863    9548067    5.06 ×10^−6^       0.00074        2.26 ×10^−6^    *SLC2A9*
  4     rs3733585    9645437    2.36 ×10^−5^       0.0015         7.19 ×10^−7^    *SLC2A9*
  4     rs6845554    9622271    1.30 ×10^−5^       0.0019         3.18 ×10^−7^    *SLC2A9*
  4     rs6827754    9627251    1.22 ×10^−5^       0.0020         3.05 ×10^−7^    *SLC2A9*
  4     rs1860910    9884568    1.35 ×10^−7^       5.25 ×10^−5^   3.28 ×10^−5^    *SLC2A9*

###### 

Quantitative association studies (PLINK) for uric acid levels in obese cases and controls (P\<1×10^−4^)

  CHR   SNP          Position(bp)   *P* (all subjects)   *P* (cases)    *P* (controls)   gene
  ----- ------------ -------------- -------------------- -------------- ---------------- ----------
  1     rs6030       167765599      3.05×10^−6^          0.0013         7×10^−5^         *F5*
  1     rs4656687    167771782      3.76×10^−5^          0.0020         0.00040          *F5*
  4     rs1506613    17558037       5.81×10^−5^          0.0028         0.041            *LCORL*
  4     rs2251890    17575646       3.38×10^−5^          0.00096        0.044            *LCORL*
  4     rs4423900    79240461       1.69×10^−5^          0.0012         0.183            *FRAS1*
  4     rs4583783    79243548       1.21×10^−5^          0.00095        0.21             *FRAS1*
  4     rs10033428   79259915       2.28×10^−5^          0.0012         0.20             *FRAS1*
  4     rs9995229    79261976       2.02×10^−5^          0.0011         0.26             *FRAS1*
  4     rs6845871    79267514       3.88×10^−5^          0.00024        0.45             *FRAS1*
  4     rs17002988   79298781       6.45×10^−6^          0.00079        0.098            *FRAS1*
  8     rs2979126    52590614       1.42 ×10^−5^         0.0050         0.063            *PXDNL*
  10    rs7092652    746109         8.72×10^−7^          0.069          0.0075           *DIP2C*
  10    rs11599917   752288         1.08×10^−6^          0.028          0.011            *DIP2C*
  10    rs877282     761532         **4.56X10^−8^**      0.0073         0.011            *DIP2C*
  10    rs1769242    777896         2.73×10^−6^          0.019          0.018            *DIP2C*
  10    rs2256711    792272         3.91×10^−6^          0.019          0.0085           *DIP2C*
  11    rs1385850    12191171       2.74×10^−5^          3.22 ×10^−5^   0.7647           *MICAL2*

###### 

Previous uric acid associated genes were replicated in our GWAS

  CHR   SNP         BP         All       cases    controls   gene
  ----- ----------- ---------- --------- -------- ---------- -----------
  4     rs2622605   89298410   0.0026    0.037    0.00017    *ABCG2*
  4     rs1481017   89316501   0.0044    0.11     0.0011     *ABCG2*
  6     rs1615495   6979458    0.00055   0.011    0.011      *RREB*
  6     rs473437    6982476    0.00052   0.0068   0.068      *RREB*
  6     rs3799344   25894972   0.0017    0.37     0.011      *SLC17A1*
  6     rs2070642   25939191   0.0084    0.35     0.10       *SLC17A1*
